Status:
RECRUITING
Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Lead Sponsor:
National Cancer Center, Korea
Collaborating Sponsors:
Seoul National University Hospital
Conditions:
Unresectable Pancreatic Cancer
Unresectable Bile Duct Carcinoma
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
* Clinical trial phase: Phase 2 * Intervention model: Control group * Group allocation: Randomized controlled trial * Research perspective: Prospective study * Participating centers: Multicenter study...
Detailed Description
Pancreatic cancer and Bile duct cancer are the 8th and 9th leading causes of all cancer in Korea, have 5-year survival rates of approximately 20%, and unresectable cancers show a poor prognosis of app...
Eligibility Criteria
Inclusion
- Patients aged at least 19 years old, diagnosed with unresectable pancreaticobiliary cancer, and scheduled to receive chemotherapy using nal-IRI/5-FU/LV combination chemotherapy
Exclusion
- Patients who refuse to sign the consent form Patients who have previously experienced severe neutropenia during chemotherapy
Key Trial Info
Start Date :
January 16 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT06135896
Start Date
January 16 2024
End Date
June 30 2026
Last Update
June 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,
Goyang-si, Gyeonggi-do, South Korea, 10408